Baseline Clinical and Blood Biomarkers in Patients With Preataxic and Early-Stage Disease Spinocerebellar Ataxia 1 and 3

In the Research Article “Baseline Clinical and Blood Biomarkers in Patients With Preataxic and Early-Stage Disease Spinocerebellar Ataxia 1 and 3” by Tezenas du Montcel et al.,¹ the methods for spinocerebellar ataxia type 1 and 3 genetic testing were not supplied or referenced. The methods used for genotyping and determination of CAG repeat lengths are now listed in eAppendix 1. In addition, those developing the methods and working on the study in Europe and the United States should have been listed as authors in the byline. Authors who contributed to genotyping include Karla P. Figueroa, Stefan M. Pulst, Anne-Laure Fauret-Amsellem, and Claudia Dufke. Among them, the omitted authors include Figueroa, Pulst, Fauret-Amsellem, and Dufke. The omitted authors and their disclosures are now listed with the article.

In addition, Appendix 2 listing the READISCA Consortium coinvestigators has been updated to include 2 previously omitted coinvestigators: William Ondo and Haris I. Sair.

The article has been replaced by a corrected version. The original version with the changes highlighted is available from a link in the corrected article. The authors regret the omissions.